Interpace Biosciences, Inc.
A molecular diagnostics company that helps doctors tell whether a suspicious thyroid nodule is cancerous, so patients can avoid needless surgery. Its lab tests, ThyGeNEXT® and ThyraMIR®, read DNA, RNA and microRNA to gauge the risk of malignancy. The business began in 2014 as the diagnostic arm of PDI, a pharmaceutical sales-services firm, and became its own company in 2015. The name "Interpace" plays on "interface," reflecting its role as a bridge between diagnosis and treatment.
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits